Evotec SE posted further revenue gains in the nine months to 30 September on the strength of several new drug discovery alliances and the receipt of milestone payments from existing collaborators. Group revenue increased by 12% to €360.4 million and included gains from both its service and proprietary drug divisions. However operating profit declined by 24% to €35.3 million due to higher spending on sales and R&D, as well as a change in tax credit regulations in Italy.
